| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8230090 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 8 Pages |
Abstract
While we await the results of the randomized trial (over 2,000 patients have already been recruited), TARGIT is an acceptable option but only in highly selected cases that cannot be recruited in the trial and in whom EBRT is not feasible/possible.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Mohammed R.S. M.D., Ph.D., F.R.C.S., Jayant S. M.D., Ph.D., F.R.C.S., Jeffrey S. M.D., F.R.C.P., F.R.C.R., Frederik M.D., David M.D., Chris Stacey, Marinos G. Ph.D., Anke Keller, Tammy Corica, Norman R. Ph.D., Michael M.D.,